BCL2 and acute myeloid leukemia: Saito et al. adopted a combination of FLT3 TKI and B-cell lymphoma 2 (Bcl-2) inhibitor in AML PDXs and identified prominently higher sensitivity to apoptosis induction compared to monotherapy[18].